journal article·2015-06-08Open access

Lipid Nanoparticles for Ocular Gene Delivery

Yuhong Wang, Ammaji Rajala, Raju Rajala

Abstract

Lipids contain hydrocarbons and are the building blocks of cells. Lipids can naturally form themselves into nano-films and nano-structures, micelles, reverse micelles, and liposomes. Micelles or reverse micelles are monolayer structures, whereas liposomes are bilayer structures. Liposomes have been recognized as carriers for drug delivery. Solid lipid nanoparticles and lipoplex (liposome-polycation-DNA complex), also called lipid nanoparticles, are currently used to deliver drugs and genes to ocular tissues. A solid lipid nanoparticle (SLN) is typically spherical, and possesses a solid lipid core matrix that can solubilize lipophilic molecules. The lipid nanoparticle, called the liposome protamine/DNA lipoplex (LPD), is electrostatically assembled from cationic liposomes and an anionic protamine-DNA complex. The LPD nanoparticles contain a highly condensed DNA core surrounded by lipid bilayers. SLNs are extensively used to deliver drugs to the cornea. LPD nanoparticles are used to target the retina. Age-related macular degeneration, retinitis pigmentosa, and diabetic retinopathy are the most common retinal diseases in humans. There have also been promising results achieved recently with LPD nanoparticles to deliver functional genes and micro RNA to treat retinal diseases. Here, we review recent advances in ocular drug and gene delivery employing lipid nanoparticles.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Lipid Membrane Structure and Behavior

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Dean A. McGee Eye Institute, Oklahoma City, OK 73104, USA

Department of Ophthalmology, College of Medicine, University of Oklahoma, Oklahoma City, OK 73014, USA

Department of Physiology and Harold Hamm Diabetes Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73014, USA

Funding

NIH

References (97)

Show source-provided references
1. Adijanto, J., and Naash, M.I. (2015). Nanoparticle-based technologies for retinal gene therapy. Eur. J. Pharm. Biopharm.10.1016/j.ejpb.2014.12.028 ↗
2. Differential binding of plasma proteins by liposomes loaded with lipophilic prodrugs of methotrexate and melphalan in the bilayer10.1134/S0006297914080070 ↗
3. Liposome supported metal oxide nanoparticles, interaction mechanism, light controlled content release, and intracellular delivery10.1002/smll.201400850 ↗
4. Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection10.1021/bi9602019 ↗
5. S/MAR-containing DNA nanoparticles promote persistent RPE gene expression and improvement in RPE65-associated LCA10.1093/hmg/ddt013 ↗
6. DNA nanoparticle-mediated ABCA4 delivery rescues Stargardt dystrophy in mice10.1172/JCI64833 ↗
7. Drug and gene delivery to the back of the eye, from bench to bedside10.1167/iovs.13-13707 ↗
8. Persistence of non-viral vector mediated RPE65 expression, case for viability as a gene transfer therapy for RPE-based diseases10.1016/j.jconrel.2013.08.299 ↗
9. Development of solid lipid nanoparticles and nanostructured lipid carriers for improving ocular delivery of acyclovir10.3109/03639045.2012.665460 ↗
10. A lipid nanoparticle system improves siRNA efficacy in RPE cells and a laser-induced murine CNV model10.1167/iovs.10-5891 ↗
11. A potential new therapeutic system for glaucoma, solid lipid nanoparticles containing methazolamide10.3109/02652048.2010.539304 ↗
12. Feasibility of lipid nanoparticles for ocular delivery of anti-inflammatory drugs10.3109/02713681003760168 ↗
13. Solid lipid nanoparticles for ocular drug delivery10.3109/10717544.2010.483257 ↗
14. Cyclosporine A loaded SLNs: Evaluation of cellular uptake and corneal cytotoxicity10.1016/j.ijpharm.2008.07.028 ↗
15. Cyclosporine A-loaded solid lipid nanoparticles, ocular tolerance and in vivo drug release in rabbit eyes10.3109/02713680903261405 ↗
16. Shen, J., Sun, M., Ping, Q., Ying, Z., and Liu, W. (2010). Incorporation of liquid lipid in lipid nanoparticles for ocular drug delivery enhancement. Nanotechnology, 21.10.1088/0957-4484/21/2/025101 ↗
17. Sustained release and permeation of timolol from surface-modified solid lipid nanoparticles through bioengineered human cornea10.1080/02713680903017500 ↗
18. Solid lipid nanoparticles for retinal gene therapy, transfection and intracellular trafficking in RPE cells10.1016/j.ijpharm.2008.04.023 ↗
19. Solid lipid nanoparticle-based calix[n]arenes and calix-resorcinarenes as building blocks, synthesis, formulation and characterization10.3390/ijms141121899 ↗
20. Lipid nanotechnology10.3390/ijms14024242 ↗
21. Diclofenac sodium delivery to the eye, in vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct10.1016/j.ijpharm.2007.12.007 ↗
22. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin10.1016/S0378-5173(02)00080-7 ↗
23. Nanoparticle-assisted targeted delivery of eye-specific genes to eyes significantly improves the vision of blind mice in vivo10.1021/nl502275s ↗
24. Micro RNA-184 modulates cannocial Wnt signaling through regulation of frizzled-7 expression in the retina with ischemia-induced neovascularization10.1016/j.febslet.2015.03.010 ↗
25. Mesoporous iron oxide nanoparticles prepared by polyacrylic acid etching and their application in gene delivery to mesenchymal stem cells10.1002/jemt.22251 ↗
26. The basic science of gene therapy10.1126/science.8493530 ↗
27. Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice10.1073/pnas.90.7.2812 ↗
28. Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates, toxicity study10.1089/hum.1993.4.6-771 ↗
29. The use of DNA viruses as vectors for gene therapy
30. Effect of genome size on AAV vector packaging10.1038/mt.2009.255 ↗
31. Gene therapy restores vision in a canine model of childhood blindness10.1038/ng0501-92 ↗
32. Gene therapy rescues cone structure and function in the 3-month-old rd12 mouse, a model for midcourse RPE65 leber congenital amaurosis10.1167/iovs.10-6138 ↗
33. Gene therapy rescues photoreceptor blindness in dogs and paves the way for treating human X-linked retinitis pigmentosa10.1073/pnas.1118847109 ↗
34. Emerging gene therapies for retinal degenerations10.1523/JNEUROSCI.0295-12.2012 ↗
35. Viral-mediated RdCVF and RdCVFL expression protects cone and rod photoreceptors in retinal degeneration10.1172/JCI65654 ↗
36. Park, K. (2014). Cornea-targeted gene therapy using adenovirus vector. J. Control. Release, 181.10.1016/j.jconrel.2014.03.042 ↗
37. How to avoid complement attack in baculovirus-mediated gene delivery10.1016/j.jip.2011.05.007 ↗
38. Luz-Madrigal, A., Clapp, C., Aranda, J., and Vaca, L. (2007). In vivo transcriptional targeting into the retinal vasculature using recombinant baculovirus carrying the human flt-1 promoter. Virol. J., 4.10.1186/1743-422X-4-88 ↗
39. Lentiviral gene transfer of RPE65 rescues survival and function of cones in a mouse model of Leber congenital amaurosis10.1371/journal.pmed.0030347 ↗
40. Nanomicelles, an emerging platform for drug delivery to the eye10.4155/tde.12.122 ↗
41. Novel biotinylated lipid prodrugs of acyclovir for the treatment of herpetic keratitis (HK), transporter recognition, tissue stability and antiviral activity10.1007/s11095-013-1059-7 ↗
42. Novel dexamethasone-loaded nanomicelles for the intermediate and posterior segment uveitis10.1208/s12249-014-0100-4 ↗
43. Ocular drug delivery10.1208/s12248-010-9183-3 ↗
44. Lipid nanoparticles as drug/gene delivery systems to the retina10.1089/jop.2012.0128 ↗
45. Liposomes as vehicles for cellular incorporation of biologically active macromolecules10.1007/BF02618199 ↗
46. Phospholipid spherules (liposomes) as a model for biological membranes10.1016/S0022-2275(20)43097-4 ↗
47. Multifunctional nanocarriers10.1016/j.addr.2006.09.009 ↗
48. Nanotechnology with soft materials10.1002/anie.200200546 ↗
49. Noble metals on the nanoscale, optical and photothermal properties and some applications in imaging, sensing, biology, and medicine10.1021/ar7002804 ↗
50. Stealth liposomes, review of the basic science, rationale, and clinical applications, existing and potential
51. Liposomes and nanotechnology in drug development, focus on ocular targets10.2147/IJN.S30725 ↗
52. Effects of sterols on the therapeutic efficacy of liposomal amphotericin B in murine candidiasis10.1089/cdd.1983.1.37 ↗
53. Liposomes in immunology, multilamellar phosphatidylcholine liposomes as a simple, biodegradable and harmless adjuvant without any immunogenic activity of its own10.3109/08820138009065997 ↗
54. Drug transport to brain with targeted liposomes10.1602/neurorx.2.1.99 ↗
55. Lipoplex formation under equilibrium conditions reveals a three-step mechanism10.1016/S0006-3495(00)76396-X ↗
56. Biodistribution and transgene expression with nonviral cationic vector/DNA complexes in the lungs10.1038/sj.gt.3301282 ↗
57. High-efficiency transfer of cystic fibrosis transmembrane conductance regulator cDNA into cystic fibrosis airway cells in culture using lactosylated polylysine as a vector10.1089/10430349950018689 ↗
58. An overview of current delivery systems in cancer gene therapy10.1016/j.jconrel.2003.09.013 ↗
59. In vivo gene transfer via intravenous administration of cationic lipid-protamine-DNA (LPD) complexes10.1038/sj.gt.3300482 ↗
60. Characterization of cationic lipid-protamine-DNA (LPD) complexes for intravenous gene delivery10.1038/sj.gt.3300683 ↗
61. Synergetic Targeted Delivery of Sleeping-Beauty Transposon System to Mesenchymal Stem Cells Using LPD Nanoparticles Modified with a Phage-Displayed Targeting Peptide10.1002/adfm.201102963 ↗
62. Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery10.1074/jbc.M007540200 ↗
63. Diffusion of univalent ions across the lamellae of swollen phospholipids10.1016/S0022-2836(65)80093-6 ↗
64. Systemic gene expression after intravenous DNA delivery into adult mice10.1126/science.7687073 ↗
65. Retinal dystrophies and gene therapy10.1007/s00431-011-1615-2 ↗
66. Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies10.1158/1078-0432.CCR-12-2046 ↗
67. Virus-mimetic cytoplasm-cleavable magnetic/silica nanoclusters for enhanced gene delivery to mesenchymal stem cells10.1002/anie.201301113 ↗
68. Understanding the mechanism of protamine in solid lipid nanoparticle-based lipofection, the importance of the entry pathway10.1016/j.ejpb.2011.06.005 ↗
69. AAV and compacted DNA nanoparticles for the treatment of retinal disorders, challenges and future prospects10.1167/iovs.10-6916 ↗
70. Advances in AAV vector development for gene therapy in the retina10.1007/978-1-4614-3209-8_86 ↗
71. A review of therapeutic prospects of non-viral gene therapy in the retinal pigment epithelium10.1016/j.biomaterials.2013.06.002 ↗
72. Comparative analysis of DNA nanoparticles and AAVs for ocular gene delivery10.1371/journal.pone.0052189 ↗
73. Viral expression cassette elements to enhance transgene target specificity and expression in gene therapy
74. Mechanistic evaluation of the transfection barriers involved in lipid-mediated gene delivery, interplay between nanostructure and composition10.1016/j.bbamem.2013.11.014 ↗
75. Nanoparticles for retinal gene therapy10.1016/j.preteyeres.2010.04.004 ↗
76. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors10.1073/pnas.151247498 ↗
77. Lipofection, a highly efficient, lipid-mediated DNA-transfection procedure10.1073/pnas.84.21.7413 ↗
78. Enhanced lipoplex-mediated gene expression in mesenchymal stem cells using reiterated nuclear localization sequence peptides10.1002/jgm.1426 ↗
79. TAT-mediated protein transduction into mammalian cells10.1006/meth.2001.1186 ↗
80. TAT transduction, the molecular mechanism and therapeutic prospects10.1016/j.molmed.2007.08.002 ↗
81. In vivo protein transduction, delivery of a biologically active protein into the mouse10.1126/science.285.5433.1569 ↗
82. In vivo protein transduction, intracellular delivery of biologically active proteins, compounds and DNA10.1016/S0165-6147(99)01429-7 ↗
83. Cell penetrating peptides, efficient vectors for delivery of nanoparticles, nanocarriers, therapeutic and diagnostic molecules10.1016/j.peptides.2014.04.015 ↗
84. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein10.1016/0092-8674(88)90262-0 ↗
85. Mutational analysis of HIV-1 Tat minimal domain peptides, identification of trans-dominant mutants that suppress HIV-LTR-driven gene expression10.1016/0092-8674(89)90417-0 ↗
86. Possible existence of common internalization mechanisms among arginine-rich peptides10.1074/jbc.M110017200 ↗
87. TAT conjugated cationic noble metal nanoparticles for gene delivery to epidermal stem cells10.1016/j.biomaterials.2014.03.062 ↗
88. Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle10.1038/3813 ↗
89. Safety and efficacy of gene transfer for Leber’s congenital amaurosis10.1056/NEJMoa0802315 ↗
90. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics10.1073/pnas.0807027105 ↗
91. Effect of gene therapy on visual function in Leber’s congenital amaurosis10.1056/NEJMoa0802268 ↗
92. Lentiviral vectors containing a retinal pigment epithelium specific promoter for leber congenital amaurosis gene therapy. Lentiviral gene therapy for LCA10.1007/0-387-32442-9_35 ↗
93. Lai, C.M., Yu, M.J., Brankov, M., Barnett, N.L., Zhou, X., Redmond, T.M., Narfstrom, K., and Rakoczy, P.E. (2004). Recombinant adeno-associated virus type 2-mediated gene delivery into the Rpe65−/− knockout mouse eye results in limited rescue. Genet. Vaccines. Ther., 2.10.1186/1479-0556-2-3 ↗
94. RPE65 gene delivery restores isomerohydrolase activity and prevents early cone loss in Rpe65−/− mice10.1167/iovs.05-0965 ↗
95. Gene therapy for retinal dystrophies, twenty years in the making10.1089/hum.2012.2506 ↗
96. Clinical gene therapy for the treatment of RPE65-associated Leber congenital amaurosis10.1517/14712598.2011.557358 ↗
97. RPE65 gene therapy slows cone loss in Rpe65-deficient dogs10.1038/gt.2012.63 ↗